Study summary

Evidence for rituximab in myasthenia gravis remains limited

Rituximab Cochrane review · Randomized trials, pooled · Published July 2025, Cochrane Database of Systematic Reviews

What was tested

A Cochrane review of rituximab, a B-cell-depleting antibody, for myasthenia gravis.

What they found

Few randomized trials exist; certainty about benefits is low.
It is widely used for MuSK-positive disease based on observational data.

What it means

Newer approved drugs have stronger trial evidence for AChR-positive disease.

Cochrane, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.